These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 12420241)

  • 21. Pharmacological venous thromboembolism prophylaxis in hospitalized medical patients: a meta-analysis of randomized controlled trials.
    Wein L; Wein S; Haas SJ; Shaw J; Krum H
    Arch Intern Med; 2007 Jul; 167(14):1476-86. PubMed ID: 17646601
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Hirudin in the treatment of arterial and venous thrombotic diseases: a new perspective.
    Büller HR
    Z Kardiol; 1993; 82 Suppl 2():81-2. PubMed ID: 8328213
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Hirudin as alternative anticoagulant--a historical review.
    Markwardt F
    Semin Thromb Hemost; 2002 Oct; 28(5):405-14. PubMed ID: 12420235
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Outpatient treatment of patients with pulmonary embolism.
    Wells PS; Büller HR
    Semin Vasc Med; 2001 Nov; 1(2):229-34. PubMed ID: 15199507
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Pharmacology of recombinant hirudin.
    Nowak G
    Semin Thromb Hemost; 2002 Oct; 28(5):415-24. PubMed ID: 12420236
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Comparative study on the antithrombotic efficacy of hirudin, heparin and a low-molecular weight heparin in preventing experimentally induced venous thrombosis.
    Monreal M; Galego G; Monreal L; Angles AM; Monasterio J; Oller B
    Haemostasis; 1993; 23(3):179-83. PubMed ID: 8276322
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Deferment of objective assessment of deep vein thrombosis and pulmonary embolism without increased risk of thrombosis: a practical approach based on the pretest clinical model, D-dimer testing, and the use of low-molecular-weight heparins.
    Siragusa S; Anastasio R; Porta C; Falaschi F; Pirrelli S; Palmieri P; Gamba G; Granzow K; Malato A; Minardi V; Tatoni P; Bressan MA; Mariani G
    Arch Intern Med; 2004 Dec 13-27; 164(22):2477-82. PubMed ID: 15596639
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Comparison of six-month outcome of patients initially treated for acute deep vein thrombosis with a low molecular weight heparin Certoparin at a fixed, body-weight-independent dosage or unfractionated heparin.
    Harenberg J; Riess H; Büller HR; Brom J; Weidinger G; Huisman MV
    Haematologica; 2003 Oct; 88(10):1157-62. PubMed ID: 14555312
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Rationale for low-molecular-weight heparin prophylaxis after total knee arthroplasty.
    Colwell CW; Hardwick ME
    Clin Orthop Relat Res; 2006 Nov; 452():181-5. PubMed ID: 17016231
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Low molecular weight heparins: the optimal treatment for venous thromboembolism.
    Daskalopoulos ME; Daskalopoulou SS; Liapis CD
    Curr Med Res Opin; 2004 Jul; 20(7):1001-5. PubMed ID: 15265244
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Evaluation of the efficacy of heparins of varying molecular mass and duration of their use in the treatment of patients with acute venous thrombosis.
    Kirienko AI; Leont'ev SG; Petukhov EB; Andreiashkin BV; Lebedev IS; Komarova VP
    Angiol Sosud Khir; 2004; 10(1):18-28. PubMed ID: 15163985
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Melagatran and ximelagatran: new drug. No real simplification of anticoagulant therapy.
    Prescrire Int; 2005 Aug; 14(78):127-32. PubMed ID: 16106594
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Thromboembolic prophylaxis in head trauma and multiple-trauma patients.
    Latronico N; Berardino M
    Minerva Anestesiol; 2008 Oct; 74(10):543-8. PubMed ID: 18475247
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A review of the risks and benefits of differing prophylaxis regimens for the treatment of deep venous thrombosis and pulmonary embolism in neurosurgery.
    Epstein NE
    Surg Neurol; 2005 Oct; 64(4):295-301; discussion 302. PubMed ID: 16181995
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The pharmacoeconomics of deep vein thrombosis treatment.
    Shorr AF
    Am J Med; 2007 Oct; 120(10 Suppl 2):S35-41. PubMed ID: 17916458
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Use of low-molecular-weight heparins in the treatment and secondary prevention of cancer-associated thrombosis.
    Grande C; Caparro M
    Semin Oncol Nurs; 2005 Nov; 21(4 Suppl 1):41-9. PubMed ID: 16360897
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Thromboprophylaxis and early antithrombotic therapy in patients with acute ischemic stroke and cerebral venous and sinus thrombosis.
    Busch M; Masuhr F
    Eur J Med Res; 2004 Apr; 9(4):199-206. PubMed ID: 15210400
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Hirudin treatment for multiple thromboses in a preterm infant with inherited thrombophilia.
    Sturm A; Speer CP; Wirbelauer J; Grossmann R
    Blood Coagul Fibrinolysis; 2007 Jun; 18(4):381-3. PubMed ID: 17473583
    [TBL] [Abstract][Full Text] [Related]  

  • 39. New therapeutic options in deep vein thrombosis prophylaxis.
    Eriksson BI
    Semin Hematol; 2000 Jul; 37(3 Suppl 5):7-9. PubMed ID: 11055889
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Drug treatment of peripheral vascular disease.
    Eberhardt RT; Coffman JD
    Heart Dis; 2000; 2(1):62-74. PubMed ID: 11728242
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.